- VCEL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $14.7 million.
- VCEL traded 374,405 shares today in the pre-market hours as of 8:02 AM, representing 12.4% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in VCEL with the Ticky from Trade-Ideas. See the FREE profile for VCEL NOW at Trade-Ideas More details on VCEL: Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Currently there is 1 analyst that rates Vericel a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Vericel has been 49,700 shares per day over the past 30 days. Vericel has a market cap of $49.7 million and is part of the health care sector and drugs industry. The stock has a beta of 0.14 and a short float of 0.3% with 0.03 days to cover. Shares are down 17.8% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Vericel as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Highlights from the ratings report include:
- Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Biotechnology industry and the overall market, VERICEL CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- VCEL's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 45.36%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- 48.17% is the gross profit margin for VERICEL CORP which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -39.04% is in-line with the industry average.
- Net operating cash flow has significantly increased by 91.47% to -$0.72 million when compared to the same quarter last year. In addition, VERICEL CORP has also vastly surpassed the industry average cash flow growth rate of 26.13%.
- VCEL's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 2.85, which clearly demonstrates the ability to cover short-term cash needs.
- You can view the full Vericel Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.